文献速递脑血管病

选择性NLRP3炎症小体抑制剂MCC950减轻脑出血后脑损伤

Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2017-12-06

该研究在小鼠自体血或细菌胶原酶诱导的脑出血模型中评估选择性NLRP3抑制剂MCC950的疗效与机制。MCC950减少IL-1β产生,减轻神经功能缺损和血肿周围脑水肿,改善血脑屏障完整性并减少细胞死亡;保护作用依赖于小胶质细胞和Gr-1+髓系细胞。提示抑制NLRP3炎症小体是脑出血的潜在疗法。

要点

  • MCC950在两种小鼠脑出血模型中减轻神经功能缺损和脑水肿。
  • MCC950减少IL-1β、白细胞浸润及小胶质细胞IL-6产生。
  • MCC950的保护作用依赖于小胶质细胞和Gr-1+髓系细胞。

核心结论

  • NLRP3炎症小体抑制剂MCC950可减轻小鼠脑出血后的脑损伤和炎症。
  • 抑制NLRP3炎症小体是脑出血的潜在疗法,值得进一步研究。

研究设计与样本

  • 研究在小鼠自体血注射或细菌胶原酶注射两种脑出血模型中评估MCC950的治疗潜力及神经保护机制。

主要发现

  • MCC950减少IL-1β产生,减轻神经功能缺损和血肿周围脑水肿。
  • 在自体血诱导脑出血小鼠中,MCC950保护作用伴随脑内白细胞浸润减少和小胶质细胞IL-6产生减少。
  • MCC950改善血脑屏障完整性并减少细胞死亡。
  • 清除小胶质细胞或Gr-1+髓系细胞后,MCC950的保护作用消失。

临床怎么用

  • 目前仅为小鼠实验证据,尚不能直接用于临床决策,但支持NLRP3炎症小体作为脑出血治疗靶点进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is a devastating disease without effective treatment. As a key component of the innate immune system, the NOD-like receptor (NLR) family, NLRP3 (pyrin domain-containing protein 3) inflammasome, when activated after ICH, promotes neuroinflammation and brain edema. MCC950 is a potent, selective, small-molecule NLRP3 inhibitor that blocks NLRP3 activation at nanomolar concentrations. Here, we examined the effect of MCC950 on brain injury and inflammation in 2 models of ICH in mice. METHODS: In mice with ICH induced by injection of autologous blood or bacterial collagenase, we determined the therapeutic potential of MCC950 and its mechanisms of neuroprotection. RESULTS: MCC950 reduced IL-1β (interleukin-1β) production and attenuated neurodeficits and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase. In mice with autologous blood-induced ICH, the protection of MCC950 was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6. MCC950 improved blood-brain barrier integrity and diminished cell death. Notably, the protective effect of MCC950 was abolished in mice depleted of either microglia or Gr-1+ myeloid cells. CONCLUSIONS: These results indicate that the NLRP3 inflammasome inhibitor, MCC950, attenuates brain injury and inflammation after ICH. Hence, NLRP3 inflammasome inhibition is a potential therapy for ICH that warrants further investigation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ren H, Kong Y, Liu Z, et al. Selective NLRP3 (Pyrin Domain-Containing Protein 3) Inflammasome Inhibitor Reduces Brain Injury After Intracerebral Hemorrhage. Stroke. 2017. PMID: 29212744. doi:10.1161/STROKEAHA.117.018904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。